Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 357
- Registration Number
- NCT04365868
- Locations
- ๐บ๐ธ
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
๐บ๐ธLoyola University Health System, Maywood, Illinois, United States
๐บ๐ธTufts Medical Center, Boston, Massachusetts, United States
A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04332432
- Locations
- ๐บ๐ธ
Clinical Pharmacology of Miami, Inc, Miami, Florida, United States
๐บ๐ธInland Empire Clinical Trials, Rialto, California, United States
๐บ๐ธTexas Liver Institute, San Antonio, Texas, United States
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT02462967
- Locations
- ๐บ๐ธ
University of California Davis Medical Center, Sacramento, California, United States
๐บ๐ธUniversity of Colorado Denver, Aurora, Colorado, United States
๐บ๐ธFlorida Digestive Health Specialist, Lakewood Ranch, Florida, United States
Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02421094
- Locations
- ๐บ๐ธ
Brooke Army Medical Center, Fort Sam Houston, Texas, United States
An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2020-09-07
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02407041
- Locations
- ๐บ๐ธ
Brooke Army Medical Ctr., San Antonio, Texas, United States
Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01899859
- Locations
- ๐บ๐ธ
Brooke Army Medical Ctr., San Antonio, Texas, United States
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Galectin Therapeutics Inc.
- Registration Number
- NCT00388700
- Locations
- ๐ฎ๐ฑ
Rambam Medical Center, Haifa, Israel
๐ฎ๐ฑKaplan MC, Rechovot, Israel
๐ฎ๐ฑSheba MC, Tel Hashomer, Israel
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Galectin Therapeutics Inc.
- Registration Number
- NCT00386516
- Locations
- ๐บ๐ธ
Boston Medical Center, Boston, Massachusetts, United States
๐บ๐ธBarrett Cancer Center, Cincinnati, Ohio, United States
๐บ๐ธUniversity of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, United States
GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2005-05-13
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00110721
- Locations
- ๐บ๐ธ
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
๐ฎ๐ฑSoroka University Medical Center, Beer-Sheva, Israel
๐บ๐ธMedical Oncology and Hematology, Waterbury, Connecticut, United States
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
- Conditions
- First Posted Date
- 2003-02-17
- Last Posted Date
- 2012-03-12
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00054977
- Locations
- ๐บ๐ธ
Florida Oncology Associates, Jacksonville, Florida, United States
๐บ๐ธUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
๐บ๐ธOchsner Cancer Institute, New Orleans, Louisiana, United States